Correlation Between Nurix Therapeutics and Foghorn Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nurix Therapeutics and Foghorn Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nurix Therapeutics and Foghorn Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nurix Therapeutics and Foghorn Therapeutics, you can compare the effects of market volatilities on Nurix Therapeutics and Foghorn Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nurix Therapeutics with a short position of Foghorn Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nurix Therapeutics and Foghorn Therapeutics.

Diversification Opportunities for Nurix Therapeutics and Foghorn Therapeutics

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Nurix and Foghorn is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Nurix Therapeutics and Foghorn Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Foghorn Therapeutics and Nurix Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nurix Therapeutics are associated (or correlated) with Foghorn Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Foghorn Therapeutics has no effect on the direction of Nurix Therapeutics i.e., Nurix Therapeutics and Foghorn Therapeutics go up and down completely randomly.

Pair Corralation between Nurix Therapeutics and Foghorn Therapeutics

Given the investment horizon of 90 days Nurix Therapeutics is expected to under-perform the Foghorn Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Nurix Therapeutics is 1.37 times less risky than Foghorn Therapeutics. The stock trades about -0.16 of its potential returns per unit of risk. The Foghorn Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  461.00  in Foghorn Therapeutics on December 29, 2024 and sell it today you would lose (73.00) from holding Foghorn Therapeutics or give up 15.84% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Nurix Therapeutics  vs.  Foghorn Therapeutics

 Performance 
       Timeline  
Nurix Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Nurix Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Foghorn Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Foghorn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Nurix Therapeutics and Foghorn Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nurix Therapeutics and Foghorn Therapeutics

The main advantage of trading using opposite Nurix Therapeutics and Foghorn Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nurix Therapeutics position performs unexpectedly, Foghorn Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foghorn Therapeutics will offset losses from the drop in Foghorn Therapeutics' long position.
The idea behind Nurix Therapeutics and Foghorn Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing